Af­ter scor­ing big Pfiz­er buy­out, a Ther­a­chon co-founder turns once again to dwarfism with $24M Se­ries A

Less than two years af­ter sell­ing her first biotech to Pfiz­er for a hefty $810 mil­lion, a French re­searcher has launched a new gene ther­a­py out­fit that’s fo­cus­ing on the same tar­get — dwarfism — but tak­ing a dif­fer­ent path to treat­ment.

The sci­en­tist is Elvire Gouze and the com­pa­ny is In­noSkel, which launched with €20 mil­lion in Se­ries A fi­nanc­ing (about $24.2 mil­lion) ear­ly Mon­day. Though In­noSkel is aim­ing to treat a whole host of rare skele­tal dis­eases that af­fect the body’s col­la­gen, it’s first go­ing af­ter what’s known as spondy­loepi­phy­seal dys­pla­sia con­geni­ta (SEDc), the sec­ond-lead­ing cause of dwarfism that stunts the growth of a pa­tient’s car­ti­lage.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER